1

10th International Congress on Peritoneal Surface MalignanciesNovember 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC

www.psogi2016.com

Course Director: Paul H. Sugarbaker, MD, FACS, FRCSMedStar Washington Hospital CenterWashington, DC

2

In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The mission of the 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients.

This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases. It will feature keynote lectures, didactic sessions, debates, meet the professor sessions with case presentations interspersed where appropriate. Extended discussions with elite panels and extensive audience participation is encouraged at this meeting.  Individual paper sessions and abstract poster presentations will also be included in the meeting. Additionally, the program will include two satellite programs on Saturday focusing on peritoneal metastases imaging and pharmacology of chemotherapy treatments.

WEDNESDAY, NOVEMBER 16

6:00 PM Welcome Reception page 6

THURSDAY, NOVEMBER 17

8:30 AM – 10:30 AM Session I: Colorectal Cancer page 6

11:00 AM – 1:00 PM Session II: Ovarian Cancer page 7

2:00 PM – 4:00 PM Session III: Lecture/Debate page 7

4:30 PM – 5:30 PM Session IV: Debate/Cases page 7

6:00 PM Networking Welcome Reception page 7

FRIDAY, NOVEMBER 18

6:30 AM – 8:00 AM Session V: Meet the Professor Breakfast Sessions page 8

8:15 AM – 9:30 AM Session VI: Gastric Cancer page 10

9:30 AM – 10:30 AM Session VII: Registries page 10

11:00 AM – 1:00 PM Session VIII: Abstracts/Cases page 11

2:00 PM – 4:00 PM Session IX: Lecture/Debate/Cases page 11

4:30 PM – 6:30 PM Session X: Lecture/Debate/Cases page 11

7:30 PM Congress Banquet with Historical Video page 11

SATURDAY, NOVEMBER 19

6:30 AM – 8:00 AM Session XI: Meet the Professor Breakfast Sessions page 9

8:15 AM – 10:30 AM Session XII: New Technologies page 12

11:00 AM – 1:00 PM Session XIII: The Future page 12

1:30 PM – 7:00 PM Post-Conference Satellite Symposium Option 1 page 13

1:30 PM – 7:00 PM Post-Conference Satellite Symposium Option 2 page 14

2

Congress at a GlanceCourse Description

3

learning objectives

• Utilize available data to determine optimal treatment options including cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, appendiceal cancer, peritoneal mesothelioma)

• Identify quantitative prognostic indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC

• Optimize patient care by discussing the use of the appropriate clinical pathways, patient protocols, and surgical procedures

• Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room

• Discuss patient selection, surgical technique and management of standardized HIPEC regiments resulting in improved patient outcomes

• Distinguish patients at risk for carcinomatosis during early phases

target audience

This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, gastroenterologists, gynecologists, pharmacologists, pathologists, advanced practice clinicians. and other healthcare professionals interested in peritoneal surface oncology.

cme accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedStar Georgetown University Hospital and MedStar Washington Hospital Center. MedStar Georgetown University Hospital is accredited by the ACCME to provide continuing medical education for physicians.

credit designation

MedStar Georgetown University Hospital designates this live activity for a maximum of 26 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. Nurses who attend a Category 1 CME certified activity can complete the continuing education hours section of the ANCC Professional Development Record in order to document the courses attended and the hours obtained.

Course Information

3

4

course directors

Paul H. Sugarbaker, MD, FACS, FRCSMedStar Washington Hospital CenterWashington, DC, USA

scientific organizing committee

David L. Bartlett, MDUniversity of Pittsburgh Medical CenterPittsburgh, PA, USA

Marcello Deraco, MDThe Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY

Olivier Glehen, MD, PhDHospitalier Lyon Sud Lyon, FRANCE

Diane Goere, MD, PhDInstitute Gustave RoussyParis, FRANCE

Santiago Gonzalez-Moreno, MD, PhDMD Anderson Cancer Center MadridMadrid, SPAIN

Yan Li, MD, PhDBeijing Shijitan Hospital Beijing, CHINA

Brendan J. Moran, MCh, FRCS, FRCSIThe North Hampshire HospitalsBasingstoke, UNITED KINGDOM

David Morris, MDSt. George Hospital Kogarah, AUSTRALIA

Pompiliu Piso, MD, PhDHospital Barmherzige Brueder Regensburg, GERMANY

Beate S. Rau, MD, PhDCharité Campus Mitte University Hospital Berlin, GERMANY

Vic Verwaal, MDAarhus University HospitalAarhus, DENMARK

Yutaka Yonemura, MD, PhDKishiwada Tokushukai HospitalOsaka, JAPAN

faculty

Nita Ahuja, MDJohns Hopkins UniversityBaltimore, MD, USA

David S. Alberts, MDUniversity of Arizona Cancer CenterTucson, AZ, USA

H. Richard Alexander Jr., MDUniversity of Maryland Medical CenterBaltimore, MD, USA

Suzanne Alves, CNSPeritoneal Malignancy InstituteBasingstoke, UNITED KINGDOM

Luca Ansaloni, MDPapa Giovanni XXIII HospitalBergamo, ITALY

Alvaro Arjona-Sanchez, MD, PhDHospital U. Reina Sofia, CordobaCordoba, SPAIN

Naoual Bakrin, MD, PhDLe Centre Hospitalier Lyon Sud Lyon, FRANCE

Dario Baratti, MDThe Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY

Joel M. Baumgartner, MD, MAS, FACSMoores Cancer CenterSan Diego, CA, USA

Lana Bijelic, MDINOVA Health SystemFalls Church, VA, USA

Gina Brown, MD, FRCRRoyal Marsden NHS Foundation TrustLondon, UNITED KINGDOM

Peter H. Cashin, MD, PhDUppsala UniversityUppsala, SWEDEN

Tom Cecil, BM, DMHampshire HospitalsBasingstoke, UNITED KINGDOM

Wim Ceelen, MD, PhDGhent UniversityGhent, BELGIUM

John K. Chan, MDPalo Alto Medical Foundation San Francisco, CA, USA

Dennis S. Chi, MDMemorial Sloan Kettering Cancer CenterNew York, NY, USA

Jean-Marc Classe, MD, PhDInstitut de Cancérologie de l’Ouest Saint-HerblainNantes, FRANCE

Eelco de Bree, MD, PhDUniversity Hospital HeraklionHeraklion, GREECE

Ignace H. de Hingh, MD, PhDCatharina Cancer InstituteEindhoven, THE NETHERLANDS

Clarisse Dromain, MD, PhDInstitute Gustave RoussyParis, FRANCE

Faculty

4

5

Jesus Esquivel, MDCancer Treatment Centers of AmericaPhiladelphia, PA, USA

Anna Fagotti, MD, PhDAgostino Gemelli UniversityRome, ITALY

Francois-Noel Gilly, MD, PhDHospices Civils de Lyon Lyon, FRANCE

Evgenia A. Halkia, MDAthens General Clinic Athens, GREECE

Nader N. Hanna, MDUniversity of Maryland School of MedicineBaltimore, MD, USA

Richard A. Hoefer Jr., DOSentara Surgery SpecialistsNewport News, VA, USA

Charles Honore, MD, PhDInstitute Gustave RoussyParis, FRANCE

Marybeth S. Hughes, MD, FACSNational Cancer InstituteBethesda, MD, USA

James S. Jelinek, MDMedStar Washington Hospital CenterWashington, DC, USA

Helen M. Kennedy, RN, STNSt. George HospitalSydney, AUSTRALIA

Joji Kitayama, MDThe University of TokyoTokyo, JAPAN

Shigeki Kusamura, MD, PhDThe Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY

Laura A. Lambert, MDUniversity of Massachusetts Medical SchoolWorcester, MA, USA

Edward A. Levine, MDWake Forest UniversityWinston-Salem, NC, USA

Gabriel Liberale, MDInstitut Jules BordetBrussels, BELGIUM

Faheez Mohamed, MDPeritoneal Malignancy InstituteBasingstoke, UNITED KINGDOM

Samantha A. Moritz, PAMedStar Washington Hospital CenterWashington, DC, USA

Garrett M. Nash, MD, MPHMemorial Sloan Kettering Cancer CenterNew York, NY, USA

Sang-Yoon Park, MD, PhDNational Cancer CenterGoyang, REPUBLIC OF KOREA

Marc Pocard, MD, PhDLariboisière HospitalSt. Louis HospitalParis, FRANCE

Francois Quenet, MDInstitut Du Cancer De MontpellierMontpellier, FRANCE

Steven A. Rosenberg, MD, PhDNational Cancer InstituteBethesda, MD, USA

Pascal Rousset, MD, PhDCentre Hospitalier Lyon SudLyon, FRANCE

David P. Ryan, MDMassachusetts General HospitalBoston, MA, USA

Paolo Sammartino, MD, PhDOspendale Policlinico UmbertoRome, ITALY

Armando Sardi, MD, FACSMercy Medical CenterBaltimore, MD, USA

John D. Spiliotis, MD, PhDMetaxa Cancer HospitalPireus, GREECE

Pieter J. Tanis, MD, PhDUniversity of AmsterdamAmsterdam, THE NETHERLANDS

Antonios-Apostolos K. Tentes, MD, PhDMetropolitan HospitalAthens, GREECE

Kiran K. Turaga, MD, MPHUniversity of ChicagoChicago, IL, USA

Kurt Van der Speeten, MD, PhDZiekenhuis Oost-Limburg Hasselt, BELGIUM

Willemien van Driel, MD, PhDNetherlands Cancer Institute- Antoni Van LeeuwenhoekAmsterdam, THE NETHERLANDS

Stephanie L. Wethington, MDMedStar Washington Hospital CenterWashington, DC, USA

Frans A.N. Zoetmulder, MD, PhDZomba Central HospitalZomba, MALAWI

5

6

6:00 PM Registration & Welcome Reception

7:00 AM Registration & Breakfast

8:00 AM Welcome Remarks Paul H. Sugarbaker, MD, FACS, FRCS

8:15 AM Welcome Comments from Local Dignitary Steven A. Rosenberg, MD, PhD

SESSION I: UPDATE ON CLINICAL TRIALS IN COLORECTAL CANCER Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS

PROACTIVE PROTOCOLS:8:30 AM ProphyloCHIP: CRS and HIPEC with Second-Look Surgery Diane Goere, MD, PhD

8:40 AM PRODIGE 7: Adjuvant ± HIPEC for Peritoneal Metastases from Colon Cancer Francois Quenet, MD

8:50 AM COLOPEC: Adjuvant HIPEC for Primary Colon Cancer Pieter J. Tanis, MD, PhD

9:00 AM PROMENADE: Prophylactic HIPEC for Primary Colon Cancer Paolo Sammartino, MD, PhD

TREATMENT PROTOCOLS:9:10 AM ICARuS EPIC FUDR versus HIPEC after Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum with Isolated Peritoneal Metastasis Garrett M. Nash, MD, MPH

9:20 AM Surgery and Oxaliplatin or Mitomycin C in Treating Patients with Tumors of the Appendix Edward A. Levine, MD

9:30 AM Cytoreduction and Intraperitoneal Chemotherapy versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Peter H. Cashin, MD, PhD

9:40 AM COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer Pompiliu Piso, MD, PhD

9:50 AM Current Status and Future Prospects for Clinical Trials in Peritoneal Metastases from Colorectal Cancer Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS Panelists: P. Cashin, D. Goere, E. Levine, G. Nash, P. Piso, F. Quenet, P. Sammartino, P. Tanis

10:30 AM Break

Wednesday, November 16

Thursday, November 17

6

7

SESSION II: UPDATE ON CLINICAL TRIALS IN OVARIAN CANCER Moderators: Luca Ansaloni, MD; Dennis S. Chi, MD

11:00 AM CRS and HIPEC in Recurrent Ovarian Cancer John D. Spiliotis, MD, PhD

11:10 AM HIPEC with Carboplatin for Recurrent Ovarian Cancer, Phase II Dennis S. Chi, MD

11:20 AM CHIPOR CRS with or without HIPEC for Relapsed Ovarian Cancer Jean-Marc Classe, MD, PhD

11:30 AM CHORINE CRS with or without HIPEC Upfront for Primary Ovarian Cancer Luca Ansaloni, MD

11:40 AM HORSE CRS with or without HIPEC in Ovarian Cancer Recurrence Anna Fagotti, MD, PhD

11:50 AM Secondary Debulking Surgery ± Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Willemien van Driel, MD, PhD

12:00 PM Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Armando Sardi, MD, FACS

12:10 PM HIPEC in Primary Ovarian Cancer, NCC Korea Sang-Yoon Park, MD, PhD

12:20 PM Gynecologic Oncology Group 252, IP Carboplatin versus IP Cisplatin John K. Chan, MD

12:30 PM Current Status and Future Prospects for Clinical Trials in Ovarian Cancer Moderators: Luca Ansaloni, MD and Dennis S. Chi, MD Panelists: J. Chan, D. Chi, J. Classe; A. Fagotti, S. Park, A. Sardi, J. Spiliotis, W. van Driel

1:00 PM Lunch & Visit the Posters and Exhibits

SESSION IIIModerator: David Morris, MD

2:00 PM Keynote Lecture (1): Animal Models: What Can They Tell Us about the Management of Peritoneal Metastases Ignace H. de Hingh, MD, PhD

2:30 PM Debate (1): Adjuvant HIPEC is Superior to Second-look Surgery with HIPEC in High Risk Primary Colorectal Cancer for Peritoneal Metastases Paolo Sammartino, MD, PhD (Pro) vs. Diane Goere, MD, PhD (Con)

3:00 PM Presentation of Best Abstracts (1-4)

4:00 PM Break

SESSION IVModerator: Diane Goere, MD, PhD

4:30 PM Debate (2): CRS and HIPEC is the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases Wim Ceelen, MD, PhD (Pro) vs. David P. Ryan, MD (Con)

5:00 PM Case Presentations (1): Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer Moderators: Dario Baratti, MD; Paul H. Sugarbaker, MD, FACS, FRCS Panelists: D. Bartlett, S. Gonzalez-Moreno, M. Pocard, D. Ryan, V. Verwaal

NETWORKING WELCOME RECEPTION6:00 PM

7

8

On Friday November 18th and Saturday November 19th, 2016, the 10th International Congress on Peritoneal Surface Malignancies will host (10) morning sessions that will also include a continental breakfast. Each session will highlight a specific topic in a small group setting with internationally renowned leaders in the field. The breakout sessions are listed below. Space is limited; please make sure to select one breakout session per day in your registration to confirm participation.

friday, november 18, 2016 | 6:30 am – 8:00 am

1. Drugs, Doses, and Duration of Treatments to Standardize HIPEC and EPIC for Colorectal, Appendiceal, Gastric, Ovarian, and Peritoneal Mesothelioma Wim Ceelen, MD, PhD; Eelco de Bree, MD, PhD; Kurt Van der Speeten, MD, PhD

2. Molecular Assessment in the Management of Peritoneal Metastases Nita Ahuja, MD; H. Richard Alexander Jr., MD; Edward A. Levine, MD

3. Proactive Management of Colorectal and other Cancers using Adjuvant HIPEC or Second-Look Surgery Tom Cecil, BM, DM; Diane Goere, MD, PhD; Charles Honore, MD, PhD ; Gabriel Liberale, MD; David Morris, MD; Pieter J. Tanis, MD, PhD

4. Starting a New Peritoneal Surface Oncology Program Dario Baratti, MD; Dennis S. Chi, MD; Beate S. Rau, MD, PhD; Vic Verwaal, MD

5. NIPS and Surgery for Gastric Cancer Joji Kitayama, MD; Francois Quenet, MD; Yutaka Yonemura, MD, PhD

6. ESSO/PSOGI Certificate in Peritoneal Surface Oncology Marcello Deraco, MD; Santiago Gonzalez-Moreno, MD, PhD

7. Unusual Diseases are Treated by CRS and HIPEC: How to Select Patients who will Benefit Luca Ansaloni, MD; Lana Bijelic, MD, Marybeth S. Hughes, MD, FACS; Paul H. Sugarbaker, MD, FACS, FRCS

8. Neoadjuvant, Adjuvant and Long-term IP/IV Chemotherapy, HIPEC, EPIC for Ovarian Cancer Naoual Bakrin, MD, PhD; Jean-Marc Classe, MD, PhD; Anna Fagotti, MD, PhD; Evgenia A. Halkia, MD; Sang-Yoon Park, MD, PhD; Willemien van Driel, MD, PhD; Stephanie L. Wethington, MD

9. Pseudomyxoma Peritonei: Natural History and Treatment Yan Li, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI

10. Nurses, APCs and Allied Healthcare Professionals: Patient’s Journey with Peritoneal Malignancy – Part 1 Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Laura A. Lambert, MD; Samantha A. Moritz, PA  

Meet the Professor Breakfast Sessions

8Underline = Session Chairperson

9

saturday, november 19, 2016 | 6:30 am – 8:00 am

11. Global Guidelines for Management of Peritoneal Mesothelioma H. Richard Alexander Jr., MD; Marcello Deraco, MD; Kiran K. Turaga, MD, MPH

12. Pseudomyxoma Peritonei: Follow-up and Management of Recurrent Disease Tom Cecil, BM, DM; Nader N. Hanna, MD; John D. Spiliotis, MD, PhD

13. Intraperitoneal Ports: When, Where, Why, How, Always or Never? Lana Bijelic, MD; John K. Chan, MD; Sang-Yoon Park, MD, PhD

14. Peritoneal Metastases from Small Bowel Adenocarcinoma: Results of Treatment Eelco de Bree, MD, PhD; Ignace H. de Hingh, MD, PhD; Yutaka Yonemura, MD, PhD

15. Surgical Complications and Return to the OR Richard A. Hoefer Jr., DO; Pompiliu Piso, MD, PhD; Vic Verwaal, MD

16. Laparoscopy and Peritoneal Surface Malignancy Jesus Esquivel, MD; Olivier Glehen, MD, PhD; Gabriel Liberale, MD; Marc Pocard, MD, PhD; Kurt Van der Speeten, MD, PhD

17. Peritoneal Metastases and Liver Metastases David L. Bartlett, MD; Joel M. Baumgartner, MD, MAS, FACS; Diane Goere, MD, PhD

18. Balancing the Books for CRS and HIPEC in a Diminishing Economy, a Global Exploration Wim Ceelen, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI; Garrett M. Nash, MD, MPH

19. Consensus Regarding Concerning Radiologic Features Used to Select Patients for CRS and HIPEC

Gina Brown, MD, FRCR; Clarisse Dromain, MD, PhD; James S. Jelinek, MD; Armando Sardi, MD, FACS; Paul H. Sugarbaker, MD, FACS, FRCS

20. Nurses, APCs and Allied Healthcare Professionals: Patient’s Journey with Peritoneal Malignancy – Part 2 Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Faheez Mohamed, MD; Samantha A. Moritz, PA

The 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) aims at improving the knowledge, treatment and outcome regarding peritoneal surface malignancies. The Scientific Organizing Committee requests participants to submit an abstract to present at the PSOGI 2016 conference. In order to promote multidisciplinary discussions during the conference, all involved disciplines such as surgery, radiology, medical oncology, pathology, and pharmacology are encouraged to submit abstracts to the program. PSOGI 2016 intends to create sufficient room for papers and posters to be presented. Selected abstracts will be incorporated into the plenary sessions for oral presentation.

recognition

Selected authors will be asked to provide an abstract poster at the meeting, November 17-19, 2016. All abstracts will be published in the official PSOGI 2016 program book.

submission details

• Abstracts must be submitted electronically at www.psogi2016.com by August 1, 2016.

• All abstract submitters will be notified of acceptance status no later than September 2, 2016.

• If you have any questions, please call 202- 780-1655 or send an email to psogi2016@gmail.com.

For categories and information regarding rules and regulations,please visit www.psogi2016.com.

Call for Abstracts

9Underline = Session Chairperson

10

SESSION V: MEET THE PROFESSOR BREAKFAST SESSIONS

6:30 AM Registration and Meet the Professor Breakfast Sessions (See page 8 for more Information)

SESSION VI: UPDATE ON CLINICAL TRIALS IN GASTRIC CANCERModerators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD

8:15 AM Opening Comments and Presentation of the Events of the Day Paul H. Sugarbaker, MD, FACS, FRCS

8:30 AM GastriCHIP Gastrectomy ± HIPEC as Adjuvant for Primary Gastric Cancer Olivier Glehen, MD, PhD

8:40 AM NIPOX Adjuvant Intraperitoneal Oxaliplatin for Gastric Cancer with Peritoneal Metastases Francois Quenet, MD

8:50 AM GASTRIPEC Cytoreductive Surgery (CRS) with/without HIPEC in Gastric Cancer with Peritoneal Carcinomatosis Beate S. Rau, MD, PhD

9:00 AM Phoenix GC Neoadjuvant Intraperitoneal and Systemic Chemotherapy (NIPS) for Gastric Cancer with Peritoneal Metastases Joji Kitayama, MD

9:10 AM Current Status and Future Prospects for Clinical Trials in Gastric Cancer Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD Panelists: O. Glehen, J. Kitayama, F. Quenet, P. Sugarbaker

SESSION VII: UPDATE ON INTERNATIONAL PERITONEAL METASTASES REGISTRIESModerators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH

9:30 AM International Registry on Peritoneal Mesothelioma Shigeki Kusamura, MD, PhD

9:40 AM Big RENAPE including Rare Diseases Treated with CRS and HIPEC Diane Goere, MD, PhD

9:50 AM German Registry Pompiliu Piso, MD, PhD

10:00 AM Dutch Registry Vic Verwaal, MD

10:10 AM Current Status and Future Prospects for Peritoneal Metastases Registries Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH Panelists: J. Esquivel, D. Goere, S. Kusamura, M. Pocard, V. Verwaal

10:30 AM Break

Friday, November 18

10

11

SESSION VIIIModerator: Beate S. Rau, MD, PhD

11:00 AM Presentation of Best Abstracts (5-8) Yutaka Yonemura, MD, PhD

12:00 PM Case Presentations (2): Peritoneal Metastases from Gastric Cancer Moderators: Beate S. Rau, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS Panelists: O. Glehen, N. Hanna, J. Kitayama, Y. Yonemura

1:00 PM Lunch & Visit the Posters and Exhibits

SESSION IXModerator: Yutaka Yonemura, MD, PhD

2:00 PM Keynote Lecture (2): Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases Joji Kitayama, MD

2:30 PM Debate (3): Recurrent Ovarian Cancer: CRS and HIPEC is a Reasonable Treatment Option Now in Selected Patients Naoual Bakrin, MD, PhD (Pro) vs. Stephanie L. Wethington, MD (Con)

3:00 PM Case Presentations (3): CRS and HIPEC for Unusual Diseases Moderators: Paul H. Sugarbaker, MD, FACS, FRCS; Vic Verwaal, MD Panelists: D. Bartlett, E. de Bree, M. Deraco, D. Goere, A. Tentes

4:00 PM Break

SESSION XModerator: Yan Li, MD, PhD

4:30 PM Keynote Lecture (3): Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain Alvaro Arjona-Sanchez, MD, PhD

5:00 PM Debate (4): Pharmacology and Clinical Data Show that Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer Joel M. Baumgartner, MD, MAS, FACS (Pro) vs. Olivier Glehen, MD, PhD (Con)

5:30 PM Case Presentations (4): The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer Moderators: Anna Fagotti, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS Panelists: L. Ansaloni, D. Chi, J. Spiliotis, W. van Driel, S. Wethington

6:30 PM Closing Remarks Paul H. Sugarbaker, MD, FACS, FRCS

CONGRESS BANQUET WITH HISTORICAL VIDEO | 7:30 PMComments by Francois-Noel Gilly, MD, PhD and Frans A.N. Zoetmulder, MD, PhD

Presentation of Certificates for European School of Peritoneal Surface Oncology

11

12

SESSION XI: MEET THE PROFESSOR BREAKFAST SESSIONS

6:30 AM Registration and Meet the Professor Breakfast Sessions (See page 9 for more Information)

SESSION XII: NEW TECHNOLOGIES TO OPTIMIZE MANAGEMENT OF PERITONEAL SURFACE MALIGNANCYModerator: David L. Bartlett, MD

8:15 AM Opening Comments and Presentation of the Events of the Day Paul H. Sugarbaker, MD, FACS, FRCS

8:30 AM Keynote Lecture (4): Genomic Medicine as it Involves Peritoneal Metastases Nita Ahuja, MD

9:00 AM Preoperative Assessments Jesus Esquivel, MD

9:20 AM Pressurized Intraperitoneal Chemotherapy (PIPAC) Marc Pocard, MD, PhD

9:30 AM Multi-Detector CT to Identify Poor Prognostic Factors in Primary Colorectal Cancer Gina Brown, MD, FRCR

10:00 AM Keynote Lecture (5): Bidirectional Adjuvant Normothermic Chemotherapy (BANC) Long-Term for Management of Ovarian Cancer John K. Chan, MD

10:30 AM Break

SESSION XIII: THE FUTURE IS NOWModerator: H. Richard Alexander Jr., MD

11:00 AM Keynote Lecture (6): 90% of the Adverse Outcomes Occur in 10% of Patients. Can We Identify the High Risk Groups? Charles Honore, MD, PhD

11:30 AM Case Presentations (5): Prevention and Treatment of Peritoneal Metastases from Appendiceal Cancer Moderators: H. Richard Alexander Jr., MD; Paul H. Sugarbaker, MD, FACS, FRCS Panelists: D. Bartlett, S. Gonzalez-Moreno, B. Moran, D. Morris, P. Tanis

12:30 PM 10 Take Home Messages Santiago Gonzalez-Moreno, MD, PhD

12:45 PM Closing Remarks and Looking Ahead to PSOGI Congress 2018 in Paris Olivier Glehen; MD, PhD, Diane Goere, MD, PhD; Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS

1:00 PM Adjourn

Saturday, November 19

12

13

SESSION IModerators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD

1:30 PM Pharmacodynamics of Intraperitoneal Chemotherapy Wim Ceelen, MD, PhD

2:00 PM Pharmacokinetics of Chemotherapy Delivery by PIPAC Marc Pocard, MD, PhD

2:30 PM Novel Approaches to Intraperitoneal Drug Delivery David Morris, MD

3:00 PM Long-Term IP/IV Chemotherapy for Ovarian Cancer: Rationale and Pharmacology John K. Chan, MD

3:30 PM Questions & Discussion Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD Panelists: W. Ceelen, J. Chan, D. Morris, M. Pocard

4:00 PM Break

SESSION IIModerator: David Morris, MD; Marc Pocard, MD, PhD

4:30 PM Pharmacology of Intraperitoneal Chemotherapy for Ovarian Cancer David S. Alberts, MD

5:00 PM Molecular Agents for Intraperitoneal Administration Olivier Glehen, MD, PhD

5:30 PM Nanomicellar Drugs for Intraperitoneal Administration Joji Kitayama, MD

6:00 PM Knowing What We Know Now, the Optimal Perioperative Chemotherapy Regimens are… Kurt Van der Speeten, MD, PhD

6:30 PM Questions & Discussion Moderator: David Morris, MD; Marc Pocard, MD, PhD Panelists: D. Alberts, O. Glehen, J. Kitayama, K. Van der Speeten

7:00 PM Adjourn

SATELLITE SYMPOSIUM (OPTION 1) Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPECThis satellite symposium will describe the pharmacodynamics and pharmacokinetics of chemotherapy administered with heat in the operating room. Additionally, novel approaches to intraoperative and long-term combined intraperitoneal and systemic chemotherapy will be investigated. Exploration of ovarian cancer molecular agents for intraperitoneal administration will also take place. The program will include ample time for questions and faculty will provide key recommendations for a standardized chemotherapy regimens for peritoneal metastases.

Saturday Post-Conference Satellite Symposia

13

14

SESSION IModerators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD

1:30 PM An Initial Attempt to Standardize a Best Technology of CT, MRI, PET for Peritoneal Metastases Clarisse Dromain, MD, PhD

2:00 PM Formulating a Lexicon of Concerning Radiologic Features James S. Jelinek, MD

2:30 PM Description of Peritoneal Metastases by CT Gina Brown, MD, FRCR

3:00 PM Description of Peritoneal Metastases by MRI Pascal Rousset, MD, PhD

3:30 PM Questions & Discussion Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD Panelists: G. Brown, P. Rousset

4:00 PM Break

SESSION IIModerator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD

4:30 PM Optical Imaging for Detection of Peritoneal Metastases Gabriel Liberale, MD

5:00 PM Using Radiology to Define High Risk for Peritoneal Metastases in Primary Gastrointestinal Cancer, Colon, Gastric, and Pancreas Gina Brown, MD, FRCR

5:35 PM Peritoneal Metastases: Their Associated Clinical Features- Can PET be of Help? Clarisse Dromain, MD, PhD

6:00 PM Is There a Minimal Required Report for Peritoneal Metastases? Pascal Rousset, MD, PhD

6:30 PM Questions & Discussion Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD Panelists: G. Brown, G. Liberale, P. Rousset

7:00 PM Adjourn

SATELLITE SYMPOSIUM (OPTION 2) Peritoneal Metastases ImagingThrough a collaboration of an international planning team to standardize the technology and terminology for imaging peritoneal metastases, this symposium will explore the clinical utility of radiologic studies to select patients who will benefit from the surgical treatment of peritoneal metastases.

14

Saturday Post-Conference Satellite Symposia

15

registration fees

NOW through September 1, 2016$500 Physician$350 Residents/Fellow$350 Advanced Practice Clinician$350 Nurse$350 Allied Health Professional

September 2 through November 15, 2016* $700 Physician $550 Residents/Fellow $550 Advanced Practice Clinician $550 Nurse $550 Allied Health Professional

*An additional $100 will be added to onsite registrations November 16-19

Post-Conference Satellite Symposia (Additional Fee) $150 Physician $100 Residents/Fellow $100 Advanced Practice Clinician $100 Allied Health Professional

Please visit our secure website at www.psogi2016.com to register to attend. We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at psogi2016@gmail.com or 202-780-1655.

cancellation policy

Cancellations made in writing by Friday, September 30, 2016 will be subject to a 50% penalty. No refunds will be given after September 30, 2016. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-780-1655 or email psogi2016@gmail.com if you any questions or need any additional information.

venue information

Omni Shoreham Hotel 2500 Calvert Street, NW, Washington, DC 20008202-234-0700

room block

Room Block Rate: $239 night plus applicable tax, single or double occupancy

Please call Omni Reservations at 1-800-THE-OMNI (1-800-843-6664) to book your room today! Reservations can also be made online by visiting psogi2016. When making reservations by phone, please indicate that you are a part of the “10th International Congress on Peritoneal Surface Malignancies Group.”

Our preferred discount room block is available Monday, November 14th, 2016 through Tuesday, November 22nd, 2016. Reservation requests received after that date will be based on availabilty at the hotel's prevailing rates.

The cut-off date for making reservations is Friday, October 21, 2016.

Registration Information

15

16

NON-PROFIT ORG.U.S. POSTAGE

PAIDMEDSTAR

WASHINGTONHOSPITALCENTER

3007 Tilden Street, NW, Suite 3NWashington, DC 2000810th International Congress on

Peritoneal Surface MalignanciesNovember 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC

www.psogi2016.com

Course Director: Paul H. Sugarbaker, MD, FACS, FRCSMedStar Washington Hospital CenterWashington, DC